Skip to main content
. 2017 May 31;8:15648. doi: 10.1038/ncomms15648

Figure 1. High-dose gp96-mediated immune-regulatory response requires CD91+ DCs.

Figure 1

(a) The experimental set-up to test the role of CD91+ DCs in HSP-mediated immune-regulatory response. Immunization was carried out using irradiated D122 (Groups 1 and 3) or control PBS (Group 2). Suppression of anti-tumour immunity, primed by irradiated D122, was mediated by high-dose (HD) gp96 treatment (Group 3) or control PBS (Groups 1 and 2). All mice were challenged with D122 and tumour growth was monitored. (b) Tumour growth in wild-type littermates (CD91f/f). (c) Tumour growth in mice lacking expression of CD91 in CD11c+ cells (CD91f/fCD11cre). Shown is the average tumour diameter ± s.e.m. n=3–5/group, data are from one representative experiment of three independent experiments. (The value of s.e.m. in Group 3 is too small to be seen in the graph). Data are represented as mean±s.e.m. ns not significant, *P<0.05 versus control (area under curve).